Gilead plans to skip from Phase 1 to Phase 3 with once-yearly PrEP drugnews2025-03-11T17:37:42+00:00March 11th, 2025|Endpoints News|
Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patientsnews2025-03-11T10:56:49+00:00March 11th, 2025|Endpoints News|
Beam shares promising first clinical data on gene editing treatmentnews2025-03-10T15:42:30+00:00March 10th, 2025|Endpoints News|
#AAD25 roundup: Data from Amgen, Bristol Myers, J&J, Alumis and morenews2025-03-10T15:37:26+00:00March 10th, 2025|Endpoints News|
FDA blocks drug and device reviewers from taking HHS’ buyout offernews2025-03-10T15:29:39+00:00March 10th, 2025|Endpoints News|
Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trialnews2025-03-10T15:20:49+00:00March 10th, 2025|Endpoints News|
J&J, Protagonist outline first IBD win for potential immunological blockbusternews2025-03-10T15:04:34+00:00March 10th, 2025|Endpoints News|
Trevi Therapeutics stock soars on Phase 2a chronic cough datanews2025-03-10T14:51:40+00:00March 10th, 2025|Endpoints News|
Arrowhead reveals small batch of open-label data for ‘non-core’ kidney drugnews2025-03-10T14:07:58+00:00March 10th, 2025|Endpoints News|
Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trialnews2025-03-10T11:21:18+00:00March 10th, 2025|Endpoints News|
